OTCMKTS:ZLDPF FY2025 EPS Estimate Lowered by William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) – Equities research analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Zealand Pharma A/S in a report issued on Wednesday, March 12th. William Blair analyst A. Hsieh now forecasts that the company will earn ($2.27) per share for the year, down from their prior forecast of ($2.26). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.19) per share. William Blair also issued estimates for Zealand Pharma A/S’s Q2 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.18) EPS and FY2027 earnings at ($2.70) EPS.

Separately, Cantor Fitzgerald raised Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Stock Down 14.6 %

ZLDPF opened at $84.50 on Friday. Zealand Pharma A/S has a fifty-two week low of $71.20 and a fifty-two week high of $141.74. The business has a 50-day moving average of $97.35 and a 200-day moving average of $109.07. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The company has a market capitalization of $6.00 billion, a PE ratio of -35.81 and a beta of 0.92.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The company had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $28.11 million.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.